Full Text
The FDA Black Box Warning Does Reduce the Use of Erythropoietin Stimulating Agents and Increases Blood Transfusions in Insured, Low Income Cancer Patients

Abstract

Authors

V. Noxon C. Bennett J. Wu

Back to Volume 17, Issue 7
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×